Products - Diabetes | Topic | NICE

Showing 20 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1137)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2026
Tirzepatide for treating type 2 diabetes (TA924)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 September 2025
Published:
25 October 2023
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 September 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2023
Published:
27 February 2013
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2023
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2022
Faricimab for treating diabetic macular oedema (TA799)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
23 November 2016
Published:
26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2008